HEALTHCARE

08 Jul 2014

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

  • In older, untreated AML patients not suitable for intensive chemotherapy, volasertib* combined with chemotherapy led to prolonged survival times compared to chemotherapy alone
  • Volasertib* also more than doubled remission rates
  • AML is a rare type of aggressive cancer of the bone marrow and blood predominantly affecting adults over 60

...

Continue Reading

08 Jul 2014

Iroko Pharmaceuticals Announces First International Filing for ZORVOLEX®

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced the company affiliate’s first regulatory submission outside of the United States for ZORVOLEX® (diclofenac) capsules. A new drug application was"...

Continue Reading

05 Jul 2014

World Leading Experts in Multiple Sclerosis to Meet in Dubai

The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MEACTRIMS) announces the First MENACTRIMS Congress for healthcare professionals to be held in Dubai, UAE. The conference will address neurologists from across the world to experience the latest research"...

Continue Reading

03 Jul 2014

U.S. Food & Drug Administration Grants Orphan Drug Designation for Galderma’s Trifarotene Molecule in the Treatment of Congenital Ichthyosis

Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to implement a clinical development plan, reinforcing its commitment to exploring new"...

Continue Reading

02 Jul 2014

02 Jul 2014

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD

  • Applications are supported by data from the >8,000 patient TOviTO™ Phase III clinical trial programme
  • First Phase III data show lung function (FEV1*) benefits of tiotropium + olodaterol fixed-dose combination† (FDC) go even beyond tiotropium (Spiriva®)1
  • Further data from TOviTO™ on patient-related outcomes such as quality...

    Continue Reading

01 Jul 2014

Egypt's military delays device that 'cures' Aids amid ridicule

A pseudo-medical device which Egypt's military had previously claimed, in the face of widespread ridicule, would cure both Aids and hepatitis C, has been delayed for "further tests" after it was slated to be made available to patients yesterday.


"...

Continue Reading

01 Jul 2014

Quintiles’ Second Quarter 2014 Earnings Call Scheduled for Thursday, July 31st

Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the second quarter of 2014 prior to its quarterly earnings call on Thursday, July 31, 2014, at 8:00 a.m. EDT.


The"...

Continue Reading

01 Jul 2014

World Bank-Aided GNRC Plans Launch of Medi-Chopper Service in North-East India

GNRC (formerly known as Guwahati Neurological Research Centre) today unveiled plans to initiate air ambulance and medical outreach programme using helicopters to remote areas of North-east India. The service will regularly ferry doctors from GNRC to difficult-to-access locations across the"...

Continue Reading

30 Jun 2014

Egypt Army says ‘AIDS-cure’ device needs more tests

Egypt’s military said Saturday that a device it claimed it invented to cure AIDS and hepatitis C needs six more months of testing.

The army had earlier promised to reveal the technology to the public this coming Monday after making what experts dismissed as an outlandish claim last February.

At a news conference then, the head of the army’s...

Continue Reading

Top News

Most Popular Articles

Found articles: 30 - Pages  « 3 
Contact US | Powered by CNPHUB.com - All Rights Reserved